Please assess the completion status of the following clinical trial:

Trial Title: A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Select Inclusion Criteria:~1. Documented histological or cytological diagnosis of renal cell cancer with a clear-cell component.~2. Measurable disease as determined by the investigator.~3. Must have received at least one VEGFR-targeting TKI (eg, sorafenib, sunitinib, axitinib, pazopanib or tivozanib).~4. Recovery from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.~5. Adequate organ and marrow function.~6. Sexually active fertile subjects(male and female)must agree to use medically accepted methods of contraception during the course of the study and for 4 months after the last dose of study treatment.~7. Female subjects of childbearing potential must not be pregnant at screening.~Select Exclusion Criteria:~1. Prior treatment with everolimus, or any other specific or selective TORC1/PI3K/AKT inhibitor (eg, temsirolimus), or cabozantinib.~2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before randomization.~3. Receipt of any type of anticancer antibody (including investigational antibody) within 4 weeks before randomization.~4. Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before randomization. Systemic treatment with radionuclides within 6 weeks before randomization. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.~5. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before randomization.~6. Concomitant anticoagulation at therapeutic doses with oral anticoagulants or platelet inhibitors.~7. Chronic treatment with corticosteroids or other immunosuppressive agents.~8. Serious illness other than cancer.~9. Major surgery within 3 months before randomization. Complete wound healing from major surgery must have occurred 1 month before randomization and from minor surgery at least 10 days before randomization.~10. Pregnant or lactating females.~11. Diagnosis of another malignancy within 2 years before randomization, except for superficial skin cancers, or localized, low grade tumors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabozantinib (XL184) (Type: EXPERIMENTAL): Cabozantinib (XL184) 60 mg tablet once daily.
- Everolimus (Afinitor) (Type: ACTIVE_COMPARATOR): Everolimus (Afinitor) 10 mg tablet once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).